RxDoctor Payments DataLook up a doctor →

Sandeep Chopra, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1952399024

Payments from drug & device makers

$14,897in general payments, 2019–2025

Across 671 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pfizer$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Boston Scientific$1K
  • Bayer$919
  • plus $7K from 28 others

What the payments were for

  • Travel & lodging$5904%
  • Food & beverage$14,27396%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,897 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$306,983
Medicare patients
658
Services billed
3,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$330,367
XareltoRivaroxaban77$109,598
CamzyosMavacamten13$109,305
EntrestoSacubitril/Valsartan56$84,622
Repatha SureclickEvolocumab97$83,904
JardianceEmpagliflozin42$50,851
FarxigaDapagliflozin Propanediol16$22,873
MultaqDronedarone Hcl11$18,719
BrilintaTicagrelor17$11,046
Metoprolol Succinate626$9,887
Atorvastatin Calcium640$8,997
Rosuvastatin Calcium378$6,016
Losartan Potassium343$5,350
Ezetimibe155$4,579
ClopidogrelClopidogrel Bisulfate233$3,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,645$330,367274 claims
Johnson & JohnsonXarelto$1,760$109,59877 claims
E.r. Squibb & Sons, L.L.C.Camzyos$776$109,30513 claims
NovartisEntresto$577$84,62256 claims
Boehringer IngelheimJardiance$545$50,85142 claims
AstraZenecaFarxiga, Brilinta$564$33,91933 claims
Sanofi-aventis U.S. LLCMultaq$664$18,71911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →